Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia

J Int Med Res. 2023 Mar;51(3):3000605231162434. doi: 10.1177/03000605231162434.

Abstract

Beta-lactam antibiotics commonly cause immune thrombocytopenia. Cross-reactivity in patients with drug-induced immune thrombocytopenia has rarely been reported. In this study, we describe the case of a 79-year-old man who developed thrombocytopenia after receiving piperacillin-tazobactam for an acute exacerbation of chronic obstructive pulmonary disease, and he was successfully treated with meropenem and cefotiam. However, thrombocytopenia recurred after cefoperazone-sulbactam administration. This indicated that cross-reactivity of platelet-specific antibodies occurred between piperacillin-tazobactam and cefoperazone-sulbactam. However, the responsible drug structures remain unknown, requiring further investigation. Likewise, chemical structure similarities among beta-lactam antibiotics must be examined to determine the risk of immune thrombocytopenia in the clinical setting.

Keywords: Piperacillin; cefoperazone; cross-reaction; sulbactam; tazobactam; thrombocytopenia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / adverse effects
  • Cefoperazone* / adverse effects
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Penicillanic Acid / adverse effects
  • Piperacillin / adverse effects
  • Piperacillin, Tazobactam Drug Combination
  • Purpura, Thrombocytopenic, Idiopathic* / drug therapy
  • Sulbactam / pharmacology
  • Sulbactam / therapeutic use

Substances

  • Cefoperazone
  • Sulbactam
  • Anti-Bacterial Agents
  • Piperacillin
  • Piperacillin, Tazobactam Drug Combination
  • Penicillanic Acid